Alamar Biosciences and DZNE Collaborate on Groundbreaking Proteomic Study

Alamar Biosciences and DZNE: Pioneering Proteomics in Disease Detection

In a significant advancement for the field of proteomics, Alamar Biosciences has officially announced a strategic partnership with the German Center for Neurodegenerative Diseases (DZNE). This collaboration aims to implement advanced proteomic profiling technologies in the renowned Rhineland Study, one of the most comprehensive longitudinal studies on aging and neurodegenerative diseases worldwide.

The partnership centers on the application of Alamar’s ultra-sensitive NULISAseq™ technology, specifically the CNS Disease Panel 120 and the Inflammation Panel 250, which will analyze a substantial dataset consisting of 23,000 longitudinal plasma samples. This endeavor seeks to enhance the detection of biomarkers that can help unravel the complexities of healthy aging and neurodegeneration.

Professor Monique Breteler, the head of Population Health Sciences at DZNE and principal investigator for the Rhineland Study, emphasized the importance of advanced technology and well-characterized cohorts in understanding aging and dementia. According to her, "The integration of Alamar’s multiplex panels into our research opens new avenues to decode the molecular signatures of brain aging."

The Rhineland Study is an expansive ongoing population cohort designed to analyze the factors that contribute to healthy aging and the emergence of neurodegenerative diseases over a lifetime. Through the NULISAseq 120 CNS Disease Panel, researchers can assess hundreds of brain-related proteins from minimal blood volumes, achieving unprecedented sensitivity and specificity in their findings. Notably, the panel's ability to distinguish phosphorylated tau derived from the brain from overall phosphorylated tau in plasma marks a transformative step for early detection and risk stratification of neurodegenerative diseases, including Alzheimer’s.

Moreover, the NULISAseq 250 Inflammation Panel delivers a comprehensive and sensitive overview of immune-related proteins involved in aging and neuroinflammation associated with neurodegenerative diseases. By merging the resultant proteomic data with extensive clinical, demographic, and imaging datasets from the Rhineland Study, researchers will be equipped to track protein changes over time, identify early biomarkers, and support the development of precision diagnostics and targeted therapies.

Yuling Luo, PhD, founder, president, and CEO of Alamar Biosciences, remarked on the collaboration: "This partnership represents a significant leap in aging and dementia research. Thanks to the unmatched sensitivity of NULISA and the deep insights offered by the DZNE Rhineland Study, we have the potential to unveil new proteomic biomarkers that reflect cognitive health trajectories and disease progression in aging populations."

This collaboration underscores a shared commitment to rigorous science, inclusivity, and innovation within the field of neurodegenerative disease research. By investigating various aging trajectories in a thoroughly characterized population, Alamar and DZNE aspire to foster earlier diagnoses, better prognostics, and new therapeutic pathways for age-related brain disorders.

About the DZNE Rhineland Study

The DZNE Rhineland Study is a pioneering population cohort that monitors thousands of individuals over decades, aiming to discover the determinants of healthy aging and neurodegeneration. Detailed clinical, imaging, genetic, and lifestyle data are collected and harmonized to provide an in-depth understanding of aging brains. To learn more about DZNE, visit www.dzne.de/en/, and for more information on the Rhineland Study, go to www.rheinland-studie.de/en/.

About Alamar Biosciences, Inc.

Alamar Biosciences is a private life sciences company dedicated to revolutionizing precision proteomics for early disease detection. Their proprietary NULISA platform, combined with the ARGO HT system, integrates the latest advancements in genomics, achieving a detection sensitivity that far surpasses the most sensitive protein detection technologies available on the market today. For additional information, visit alamarbio.com.